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Cutaneous adverse drug reactions (cADR) are common occurrences in the hospital, affecting 1-3% of all
hospitalized patients.
Although most are benign, cADR can result in severe, life-threatening disease. Mild forms include
maculopapular rash, fixed-drug eruption, morbilliform drug eruption, and urticaria. More severe reactions
include Stevens-Johnson (SJS) and drug-induced hypersensitivity syndromes (DIHS).
CASE PRESENTATION




Initial presentation of severe cADR can often mimic exanthematous drug eruptions; for example, a morbilliform eruption
occurs in 80% of DIHS while SJS/TEN can be preceded by confluent purpuric macules before blisters and erosions.
Similarities in presentations, particularly early in onset, can make triage decisions difficult for PCPs and admitting
physicians.
This patient was admitted to the ICU for, ultimately, a mild exanthematous drug eruption.
The cost of a single night in the ICU exceeds $5000. Recognizing the signs portending severe cADR will help physicians
triage patients appropriately and conserve valuable resources.
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A 37-year-old woman with a past medical history of bipolar I on
lamotrigine, PTSD, and IBS presented to the emergency
department after developing a mildly pruritic red rash on her
lower legs, abdomen, and chest. She had been diagnosed with
bipolar disorder the month prior and had been slowly up-titrating
her lamotrigine dose per her PCP’s recommendations. Her last
dose increase occurred one week prior. She also had a post-
traumatic headache which was resistant to aspirin-
acetaminophen-caffeine and propranolol and a recent UTI treated
with trimethoprim-sulfamethoxazole.
In the ED, she was afebrile but hypotensive with BP 80/37. Exam
was notable for diffuse erythematous macules and papules on the
lower extremities, abdomen, and chest, without bullae or urticaria
(images included below). Lymphadenopathy was absent. Mucous
membranes were normal and she was otherwise in no acute
distress.
The patient was admitted to the ICU for observation with concern
for severe cADR. Her medications were held and the rash and
hypotension resolved. She was discharged home the next day in
stable condition with PCP follow up.
Drug-induced Hypersensitivity Syndrome Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis
Organ system Finding Patient population
Cardiac Hypotension 41%
Myocarditis 4%
Troponin I elevation 0%






HEENT Facial swelling 25%
Hematologic Eosinophilia (can be delayed 1-2 weeks) 30%
Leukocytosis 58%
Hepatic Elevated transaminases 70-95%
Lymphatic Lymphadenopathy 75.0%
Neuro Meningoencephalitis Case reports
Renal Interstitial nephritis 11%
Thyroid Thyroid dysfunction Case reports
Organ system Finding Patient 
population
Cutaneous Epidermal detachment / Pseudo-Nikolsky sign 100%
Asboe-Hansen or “bulla spread” sign 100%
General Fever 70%






Hepatic Elevated transaminases 37%
Lymphatic Lymphadenopathy 30%





Renal Elevated BUN/Cr 11%
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